Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Briquilimab in Chronic Inducible Urticaria Refractory to H1-Antihistamines
2023-507534-24-00Phase 2Completed
- Sponsor
- Jasper Therapeutics, Inc.
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of briquilimab in chronic inducible urticaria (CIndU), sponsored by Jasper Therapeutics, Inc. Primary endpoints: Incidence and severity of treatment-emergent adverse events and serious adverse events, Laboratory assessments, ECG, vital signs and 1 more. Started Dec 2023; status: completed.
02
Drugs
briquilimab
03
Conditions
chronic inducible urticaria (CIndU)
Beyond the preview
Go deeper on 2023-507534-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507534-24-00.